Etoposide improves survival in high-grade glioma: A meta-analysis

Anticancer Research

Volumn 33, Issue 8, 2013, Pages 3307-3316

  Leonard, Alexis ^a   Wolff, Johannes E ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Anaplastic; Etoposide; Glioblastoma multiforme; High grade glioma; Irinotecan; Meta analysis; Teniposide; Topotecan

Indexed keywords

BEVACIZUMAB; ETOPOSIDE; IRINOTECAN; TEMOZOLOMIDE; TENIPOSIDE; TOPOTECAN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; COMPARATIVE STUDY; GLIOMA; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL;

ANAPLASTIC; ETOPOSIDE; GLIOBLASTOMA MULTIFORME; HIGH-GRADE GLIOMA; IRINOTECAN; META-ANALYSIS; TENIPOSIDE; TOPOTECAN;

BRAIN NEOPLASMS; COHORT STUDIES; DEMOGRAPHY; ETOPOSIDE; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TOPOISOMERASE INHIBITORS;

EID: 84883281070     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
2. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA and Yung WK: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17: 2572-2578, 1999.
3. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S and Levin VA: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83: 588-593, 2000.
4. Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J and Reaman GH: Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: A report from the Children's Oncology Group. Cancer 110: 1542-1550, 2007.
5. Jalali R, Raut N, Arora B, Gupta T, Dutta D, Munshi A, Sarin R and Kurkure P: Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys 77(1): 113-118, 2010.
6. Finlay J, Dhall G, Boyett J, Dunkel I, Gardner S, Goldman S, Yates A, Rosenblum M, Stanley P, Zimmerman R, Wallace D, Pollack I and Packer R: Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: Outcome compared with conventional chemotherapy: A report from the Children's Oncology Group. Pediatr Blood Cancer 51: 806-811, 2008.
7. Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC and Rowinsky EK: Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88: 734-741, 1996.
8. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M and Cloughesy T: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733-4740, 2009.
9. Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Sampson JH, McLendon RE, Herndon JE and Friedman HS: Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. J Neurooncol 95: 393-400, 2009.
10. Vredenburgh JJ, Desjardins A, Reardon DA, K. Peters, Kirkpatrick J, Herndon JE, Marcello J, Bailey L, Threatt S and Friedman HS: Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM) [abstract]. J Clin Oncol 28(15): 185, 2010.
11. Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M, Broholm H, Stockhausen MT and Poulsen HS: Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: A phase II trial. Neuro Oncol 12(5): 508-516, 2010.
12. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, McLendon RE, Herndon JE, Marcello JE, Norfleet J, Friedman AH, Bigner DD and Friedman HS: Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: A phase II study. Br J Cancer 101(12): 1986-1994, 2009.
13. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS and Fine HA: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5): 740-745, 2009.
14. Desjardins A, Reardon DA, Herndon JE 2nd, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS and Vredenburgh JJ: Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 14(21): 7068-7073, 2008.
15. Rubie H, Geoerger B, Frappaz D, Schmitt A, Leblond P, Ndiaye A, Aerts I, Le Deley MC, Gentet JC, Paci A, Chastagner P, Dias N, Djafari L, Pasquet M, Chatelut E, Landman-Parker J, Corradini N and Vassal G: Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours. Eur J Cancer 15: 2763-2770, 2010.
16. Terasaki M, Bouffet E, Katsuki H, Fukushima S and Shigemori M: Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors. Surg Neurol 69: 46-50, 2008.
17. Stark-Vance V: Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma [abstract]. J Neurooncol 7: 369, 2005.
18. Lamond JP, Mehta MP, and Boothman DA: The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: Report of a synergistic effect between topotecan and radiation. J Neurooncol 30: 1-6, 1996
19. Jeremic B, Grujicic D, Jevremovic S, Stanisavljevic B, Milojevic L, Djuric L and Mijatovic L: Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: A phase II study. J Clin Oncol 10(7): 1074-1077, 1992.
20. Wolff JE, Berrak S, Koontz Webb SE and Zhang M: Nitrosourea efficacy in high-grade glioma: A survival gain analysis summarizing 504 cohorts with 24193 patients. J Neurooncol 88(1): 57-63, 2008.
21. Aydin B, Patil M, Bekele N and Wolff JE: Vincristine in highgrade glioma. Anticancer Res 30: 2303-2310, 2010.
22. Hauch H, Sajedi M and Wolff JE: Treatment arms summarizing analysis of 220 high-grade glioma studies. Anticancer Res 25(5): 3585-3590, 2005.
23. Macdonald D, Cairncross G, Stewart D, Forsyth P, Sawka C, Wainman N and Eisenhauer E: Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group. Ann Oncol 7: 205-207, 1996.
24. Friedman HS, Kerby T, Fields S, Zilisch JE, Graden D, McLendon RE, Houghton PJ, Arbuck S, Cokgor I and Friedman AH: Topotecan treatment of adults with primary malignant glioma. Cancer 85: 1160-1165, 1999.
25. Burch PA, Bernath AM, Cascino TL, Scheithauer BW, Novotny P, Nair S, Buckner JC, Pfeifle DM, Kugler JW and Tschetter LK: A North Central Cancer Treatment Group phase II trial of topotecan in relapsed gliomas. Invest New Drugs 18: 275-280, 2000.
26. Fisher B, Won M, Macdonald D, Johnson DW and Roa W: Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: Results of Radiation Therapy Oncology Group 9513. Int J Radiat Oncol Biol Phys 53: 980-986, 2002.
27. Chamberlain MC and Grafe MR: Recurrent chiasmatichypothalamic glioma treated with oral etoposide. J Clin Oncol 13: 2072-2076, 1995.
28. Fulton D, Urtasun R and Forsyth P: Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol 27: 149-155, 1996.
29. Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O'Neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, Weiss SE, Levy B, Bradshaw J, Kracher J, Laforme A, Black PM, Folkman J, Kieran M and Wen PY: Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol 9: 354-363, 2007.
30. Ashley DM, Meier L, Kerby T, Zalduondo FM, Friedman HS, Gajjar A, Kun L, Duffner PK, Smith S and Longee D: Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 14: 1922-1927, 1996.
31. Needle MN, Molloy PT, Geyer JR, Herman-Liu A, Belasco JB, Goldwein JW, Sutton L and Phillips PC: Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediatr Oncol 29: 28-32, 1997.
32. Chamberlain MC: Recurrent brainstem glioma treated with oral VP-16. J Neurooncol 15: 133-139, 1993.
33. Chamberlain MC: Recurrent supratentorial malignant gliomas in children; long-term salvage therapy with oral etoposide. Arch Neurol 54: 554-558, 1997.
34. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH and Friedman HS: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25: 4722-4729, 2007.
35. Couec ML, André N, Thebaud E, Minckes O, Rialland X, Corradini N, Aerts I, Marec Bérard P, Bourdeaut F and Leblond P: Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends. Pediatr Blood Cancer 59(1): 34-38, 2012.
36. Raymond E, Fabbro M, Boige V, Rixe O, Frenay M, Vassal G, Faivre S, Sicard E, Germa C, Rodier JM, Vernillet L and Armand JP: Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann Oncol 14: 603-614, 2003.
37. Batchelor TT, Gilbert MR, Supko JG, Carson KA, Nabors LB, Grossman SA, Lesser GJ, Mikkelsen T and Phuphanich S: NABTT CNS Consortium: Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11. J Neurooncol 6: 21-27, 2004.
38. Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K and Kuhn J; North American Brain Tumor Consortium: A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium Study. J NeuroOncol 8: 189-193, 2006.
39. Hargrave D, Geoerger B, Frappaz D, Pietsch T, Gesner L, Cisar L, Breazna A, Dorman A, Cruz-Martinez O, Fuster JL, Rialland X, Icher C, Leblond P, Ashley D, Perilongo G, Elliott M, English M, Clausen N and Grill J: A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study. J Neurooncol 113(1): 127-134, 2013.